Coriell is using state of the art CRISPR/Cas9 technology to edit disease-specific iPSC lines from our repositories to generate isogenic iPSC lines for the broad research community. These lines offer researchers a better tool to study a mutation of interest without influence from different genetic backgrounds when comparing disease state and the control (apparently healthy state). Coriell also houses and distributes gene-edited fluorescent protein-tagged iPSC lines established by the Allen Institute. These lines allow researchers to visualize proteins important for cytoskeletal structure in real time.

Coriell is planning to offer this service to our customers in the near future.